UCB’s Post

🚀 𝑬𝒙𝒄𝒊𝒕𝒊𝒏𝒈 𝑵𝒆𝒘𝒔! 𝑪𝒍𝒊𝒏𝒊𝑶𝒑𝒔 𝑷𝒂𝒓𝒕𝒏𝒆𝒓𝒔 𝒘𝒊𝒕𝒉 𝑰𝒏𝒅𝒆𝒈𝒆𝒏𝒆 𝒕𝒐 𝑹𝒆𝒗𝒐𝒍𝒖𝒕𝒊𝒐𝒏𝒊𝒛𝒆 𝑪𝒍𝒊𝒏𝒊𝒄𝒂𝒍 𝑻𝒓𝒊𝒂𝒍𝒔  🌐 CliniOps, Inc., a leader in Digital Clinical Trial solutions, has partnered with Indegene, to create a seamless, end-to-end platform designed to accelerate clinical trials. This strategic collaboration enhances patient recruitment, data management, biostatistics, and regulatory submissions — empowering faster, more efficient global clinical trial operations, leveraging a robust 𝐔𝐧𝐢𝐟𝐢𝐞𝐝 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦. Together, we're paving the way for smarter, data-driven clinical research that can bring life-saving treatments to market faster! 💡🔬 Click here for the press release: https://lnkd.in/ehgfPynM Our team will be at this year’s 𝐉𝐏 𝐌𝐨𝐫𝐠𝐚𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞, 2025, in San Francisco, if you'd like to discuss more. #JPM2025 Abhijit Barve, MD, PhD, MBA, Gaurav Kapoor, Ram Yeleswarapu, Avik Pal #ClinicalTrials, #DigitalHealth, #Innovation, #Pharma, #Partnership, #ClinicalResearch, #Biotech, #LifeSciences, #PatientCentric, #ClinicalOps

By amplifying marginalized voices, we strengthen not only the integrity of our research but also its potential to transform the lives of patients, caregivers, and healthcare providers. Let’s commit to ensuring every voice is heard—because healthcare should leave no one behind. Read more about our POV at #Healogix ⬇️ #healthcarequity #pharmamarketresearch

🚀 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐍𝐞𝐰𝐬! 𝐂𝐥𝐢𝐧𝐢𝐎𝐩𝐬 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬 𝐰𝐢𝐭𝐡 𝐈𝐧𝐝𝐞𝐠𝐞𝐧𝐞 𝐭𝐨 𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐞 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬 🌐 CliniOps, Inc., a leader in Digital Clinical Trial solutions, has partnered with Indegene, to create a seamless, end-to-end platform designed to accelerate clinical trials. This strategic collaboration enhances patient recruitment, data management, biostatistics, and regulatory submissions — empowering faster, more efficient global clinical trial operations, leveraging a robust 𝐔𝐧𝐢𝐟𝐢𝐞𝐝 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦. Together, we're paving the way for smarter, data-driven clinical research that can bring life-saving treatments to market faster! 💡🔬 Click here for the press release: https://lnkd.in/eEypNYRX Our team will be at this year’s 𝐉𝐏 𝐌𝐨𝐫𝐠𝐚𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞, 2025, in San Francisco, if you'd like to discuss more. #JPM2025 Abhijit Barve, MD, PhD, MBA, Gaurav Kapoor, Ram Yeleswarapu, Avik Pal #ClinicalTrials #DigitalHealth #Innovation #Pharma #Partnership #ClinicalResearch #Biotech #LifeSciences #PatientCentric #ClinicalOps

𝗔𝗺𝗽𝗹𝗶𝗳𝘆𝗶𝗻𝗴 𝗠𝗮𝗿𝗴𝗶𝗻𝗮𝗹𝗶𝘇𝗲𝗱 𝗩𝗼𝗶𝗰𝗲𝘀 𝗶𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗮𝗻𝗱 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 In healthcare and pharmaceutical market research, the power of data drives decisions that shape clinical guidelines, policies, treatments, and outcomes. Yet, we must ask: whose voices are being heard in the process? Marginalized communities—whether defined by race, ethnicity, gender, socioeconomic status, or disability—are often underrepresented in research. This exclusion not only reinforces disparities but also limits our understanding of diverse healthcare needs. At Healogix, we focus on gathering diverse and representative perspectives to deliver a more accurate, realistic, and comprehensive understanding of the patient experience, healthcare provider mindset, and product receptivity. Here’s why prioritizing marginalized voices matters: • 𝗛𝗲𝗮𝗹𝘁𝗵 𝗘𝗾𝘂𝗶𝘁𝘆: Inclusive data enables equitable access to treatments, care, and resources. Without diverse representation, the industry risks perpetuating inequities in health outcomes. • 𝗖𝘂𝗹𝘁𝘂𝗿𝗮𝗹 𝗥𝗲𝗹𝗲𝘃𝗮𝗻𝗰𝗲: Healthcare solutions tailored to broader populations are more effective. Incorporating perspectives from underrepresented groups ensures messaging and communication around treatments are meaningful to all. • 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻: Diverse voices lead innovative thinking and unique strategic planning. Understanding the needs of marginalized groups sparks creativity in pharmaceutical development and delivery strategies. As professionals in healthcare and market research, it’s our collective responsibility to: • 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲 𝗕𝗶𝗮𝘀: Identify and address gaps in our sampling and methodologies. • 𝗘𝗻𝗴𝗮𝗴𝗲 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝗶𝗲𝘀: Build trust through culturally sensitive outreach, material development, research methodologies, and partnerships. • 𝗔𝗱𝘃𝗼𝗰𝗮𝘁𝗲 𝗳𝗼𝗿 𝗖𝗵𝗮𝗻𝗴𝗲: Push for policies and investments that prioritize inclusivity at every level of research and development. By amplifying marginalized voices, we strengthen not only the integrity of our research but also its potential to transform the lives of patients, caregivers, and healthcare providers. Let’s commit to ensuring every voice is heard—because healthcare should leave no one behind. 𝗥𝗲𝗮𝗰𝗵 𝗼𝘂𝘁 𝘁𝗼 Amanda Mayfield 𝗮𝘁 𝗔𝗺𝗮𝗻𝗱𝗮.𝗠𝗮𝘆𝗳𝗶𝗲𝗹𝗱@𝗵𝗲𝗮𝗹𝗼𝗴𝗶𝘅.𝗰𝗼𝗺 𝘁𝗼 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗵𝗼𝘄 𝗼𝘂𝗿 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗱𝗲𝘀𝗶𝗴𝗻, 𝗿𝗲𝗰𝗿𝘂𝗶𝘁𝗺𝗲𝗻𝘁 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀, 𝗮𝗻𝗱 𝗽𝗿𝗼𝗽𝗿𝗶𝗲𝘁𝗮𝗿𝘆 𝗺𝗲𝘁𝗵𝗼𝗱𝗼𝗹𝗼𝗴𝗶𝗲𝘀 𝗰𝗮𝗻 𝗵𝗲𝗹𝗽 𝘆𝗼𝘂𝗿 𝘁𝗲𝗮𝗺 𝗰𝗼𝗻𝗻𝗲𝗰𝘁 𝘄𝗶𝘁𝗵 𝗮 𝗱𝗶𝘃𝗲𝗿𝘀𝗲 𝗮𝗻𝗱 𝗿𝗲𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝘃𝗲 𝗮𝘂𝗱𝗶𝗲𝗻𝗰𝗲.  #Healthcare #Pharmaceuticals #HealthcareEquity #MarketResearch #Inclusion #DiversityInResearch 

Every patient should have the opportunity to access treatments that could better their lives. That’s why my colleagues at AbbVie aim to improve representation in #ClinicalTrials. See the bold steps they’re taking to drive systematic change: https://lnkd.in/dUmZKVPM #ClinicalTrialsDay #WeAreAbbVie

🚀 Innovative science and R&D funds are critical but not enough to demonstrate the clinical value of a new drug. Accelerating Clinical Trials timelines, recruitments and process are important factors to turn science into health benefits. Biopharma sponsors are striving to speed up clinical trials and cut costs through strategic actions aimed at enhancing patient and site engagement. As it stands, the limiting factor for innovation is no longer science nor funding but the speed of trial completion due to a shortage of study participants and site professionals. 🏆 Key Actions for Success: -Innovative Trial Designs: Reduce participant numbers while ensuring robust data. -Patient-Centric Protocols: Simplify processes to boost enrollment and engagement. -Data-Driven Site Selection: Leverage AI to identify and manage optimal sites. -Reimagined Delivery: Use hybrid and decentralized models to increase accessibility.  -Enhanced Site Experience: Streamline interactions and support for sites. Despite a thriving pipeline, with over 6,100 distinct drugs in development and significant investments from both government and private sectors, R&D productivity remains low. Clinical trial timelines have extended, and recruitment is increasingly challenging. 💪  Biopharma companies that evolve their clinical trial delivery models and create compelling value propositions for participants and sites will lead the way. Addressing recruitment and engagement is crucial to turning scientific advancements into tangible health benefits.#Pharma #ClinicalTrials #Innovation #PatientEngagement #Healthcare Thanks to Gaurav Agrawal and Harriet Keane for this McKinsey & Company insight. Antoine Bassel Amer

As a Chief of Staff in a tech-savvy biopharma company, I'm closely following the presidential debate today. It's always intriguing to see how our leaders plan to address crucial issues impacting innovation, healthcare, and technology. In our industry, we thrive on pushing boundaries and discovering new solutions. It's essential to have policies that not only support progress but also prioritize safety and accessibility for all individuals. Regardless of the election outcome, I remain optimistic that there will be a continued emphasis on advancing science and technology for the greater good. Excited to see how one of these candidates will shape our future. #PresidentialDebate #TechInBiopharma #Innovation #HealthcarePolicy